About: Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.37 (-6.42%)
ANNXNASDAQAnnexon Inc
Annexon Inc share price
ANNX price activity
Last Price
$4.370
Change (24hr)
-0.30 USD (-6.42%)
Volume
5.53M
Volume (4w avg)
-
Open
$4.60
Day Range
$4.34 - $4.66
Previous Close
$4.67
Last Trade
09 Sep, 8:01 pm GMT+0
Delayed
09 Sep, 8:01 pm GMT+0
ANNX price performance
Delayed
09 Sep, 8:01 pm GMT+0
ANNX Market Signals